We are live on ! Find out more
BNTX icon

BioNTech

296 hedge funds and large institutions have $5.24B invested in BioNTech in 2024 Q3 according to their latest regulatory filings, with 75 funds opening new positions, 75 increasing their positions, 94 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more capital invested

Capital invested by funds: $3.3B → $5.24B (+$1.94B)

17% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 64

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more call options, than puts

Call options by funds: $367M | Put options by funds: $317M

3% more funds holding

Funds holding: 286296 (+10)

1.35% more ownership

Funds ownership: 17.25%18.6% (+1.4%)

20% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 94

Holders
296
Holders Change
+10
Holders Change %
+3.5%
% of All Funds
4.25%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.1%
New
75
Increased
75
Reduced
94
Closed
64
Calls
$367M
Puts
$317M
Net Calls
+$50M
Net Calls Change
+$41.3M
Name Holding Trade Value Shares
Change
Change in
Stake
Baillie Gifford & Co
1
Baillie Gifford & Co
United Kingdom
$987M +$2.92M +31,773 +0.4%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$748M +$515M +5,598,190 +798%
Primecap Management
3
Primecap Management
California
$536M -$25.1M -273,000 -6%
Flossbach Von Storch
4
Flossbach Von Storch
Germany
$518M -$1.83M -19,876 -0.5%
BlackRock
5
BlackRock
New York
$246M +$16.2M +176,507 +9%
Temasek Holdings
6
Temasek Holdings
Singapore
$215M
Capital International Investors
7
Capital International Investors
California
$121M +$25.6M +278,055 +37%
CII
8
Capital International Inc
California
$111M +$67.3M +731,584 +368%
CS
9
Candriam SCA
Luxembourg
$110M +$32M +348,166 +60%
Morgan Stanley
10
Morgan Stanley
New York
$80.3M -$43.4M -471,881 -41%
AGA
11
Altrinsic Global Advisors
Connecticut
$77.5M -$2.16M -23,513 -3%
Balyasny Asset Management
12
Balyasny Asset Management
Illinois
$73.7M +$15.1M +164,548 +36%
FAM
13
Fred Alger Management
New York
$59.5M +$46M +500,844 New
DekaBank Deutsche Girozentrale
14
DekaBank Deutsche Girozentrale
Germany
$56.9M +$4.95M +53,800 +13%
First Trust Advisors
15
First Trust Advisors
Illinois
$53.6M +$3.87M +42,139 +10%
QOP
16
Quinn Opportunity Partners
Virginia
$48M -$25.6M -278,787 -41%
Voloridge Investment Management
17
Voloridge Investment Management
Florida
$47.5M +$12M +130,449 +48%
Amundi
18
Amundi
France
$44.1M +$8.53M +92,825 +34%
Point72 Asset Management
19
Point72 Asset Management
Connecticut
$43M -$9.17M -99,718 -22%
Squarepoint
20
Squarepoint
New York
$38.6M +$4.23M +46,027 +17%
T. Rowe Price Associates
21
T. Rowe Price Associates
Maryland
$37.9M +$24.5M +266,667 +511%
Deutsche Bank
22
Deutsche Bank
Germany
$35.4M -$4.85M -52,803 -15%
GGHC
23
Gilder Gagnon Howe & Co
New York
$32.8M -$135K -1,467 -0.5%
TCM
24
Tang Capital Management
California
$32.1M +$24.8M +270,000 New
LA
25
LBP AM
France
$29.4M +$22.8M +247,833 New

BNTX Hedge Fund Activity: Q3 2024 in Review

296 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q3 2024, worth a combined $5.24B — up 59% from $3.3B a quarter earlier.

Buyers outnumbered sellers: 75 funds opened new BNTX positions and 64 closed out — a net gain of 11 holders — while 75 added to existing stakes and 94 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $515M. The largest seller was Harding Loevner, cutting an estimated $269M.

  • 296 institutional investors held BioNTech (BNTX) as of Q3 2024, up from 286 in Q2 2024.
  • Funds reported $5.24B of BioNTech stock for Q3 2024, up 59% quarter-over-quarter.
  • 75 funds opened new BioNTech positions in Q3 2024 and 64 closed out, a net change of +11 holders.
  • The largest BioNTech buyer in Q3 2024 was Fidelity Investments, an estimated $515M added.
  • The largest BioNTech seller in Q3 2024 was Harding Loevner, an estimated $269M sold.

Based on aggregated 13F filings for Q3 2024.